DBV Technologies (NASDAQ: DBVT) is one of 89 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare DBV Technologies to related businesses based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Volatility and Risk
DBV Technologies has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, DBV Technologies’ competitors have a beta of 1.59, meaning that their average share price is 59% more volatile than the S&P 500.
This table compares DBV Technologies and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DBV Technologies||$13.46 million||-$166.93 million||-9.28|
|DBV Technologies Competitors||$1.05 billion||$96.04 million||0.94|
DBV Technologies’ competitors have higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares DBV Technologies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DBV Technologies Competitors||-5,580.84%||-62.17%||-25.05%|
This is a summary of current recommendations for DBV Technologies and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DBV Technologies Competitors||450||1664||4477||148||2.64|
DBV Technologies currently has a consensus target price of $48.86, suggesting a potential upside of 103.32%. As a group, “Biological products, except diagnostic” companies have a potential upside of 22.10%. Given DBV Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe DBV Technologies is more favorable than its competitors.
Insider and Institutional Ownership
39.5% of DBV Technologies shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.3% of DBV Technologies shares are owned by insiders. Comparatively, 16.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn's disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.